Wells Fargo maintains Eli Lilly at Overweight, raises price target to $1500 from $1330

What happened

Wells Fargo kept its Overweight rating on Eli Lilly and raised its price target to $1500 from $1330, a 12.8% increase. The new target implies 9.2% upside from the October 29 close of $1373.70.

Confirmed

Global impact / market context

A higher analyst price target signals one brokerage expects more share price gains. Because other firms also carry targets above the current price, it suggests broader analyst confidence in Eli Lilly's revenue and profit outlook, which can support investor demand for the stock.

Analyst inference

The five most recent analyst targets range from $1316 to $1612, placing Wells Fargo's $1500 near the middle of that spread. A tight range of bullish ratings suggests analysts largely agree on the company's direction, reducing the chance of sharp rating-driven price swings.

Analyst inference

What to watch

1. Whether other analysts change their Eli Lilly price targets or ratings, since the five latest targets already span $1316 to $1612 and could shift the range. Confirmed
2. Watch for Eli Lilly's next earnings report to see whether revenue and profit support the higher expectations implied by these analyst price targets. Proposed
3. Track whether Eli Lilly's share price moves toward the $1500 target, which would show investors accepting the growth assumptions behind the raised rating. Analyst inference

Evidence

• Original source link unavailable